12/06/2026
We're delighted to share that following a draft no decision, NICE have approved the life-extending treatment, DVRD, for use on the NHS in England and Wales.
We submitted more data and evidence to NICE’s appraisal committee and, along with clinicians and the pharmaceutical company behind the treatment, successfully made the case for DVRD to be rolled out on the NHS.
DVRD is aimed at newly-diagnosed patients who are not eligible for a stem cell transplant. It combines daratumumab (Darzalex®), bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone.
The latest trial data shows that 68% of people on DVRD were still in remission after four and a half years.
Caroline Donoghue, our Access Manager, said:
“This is fantastic news and a great result for patients who felt let down by NICE’s initial decision not to approve DVRD. We have been working very hard to get NICE to reconsider and we’re delighted they’ve agreed to roll it out on the NHS. We know how devastating being diagnosed with myeloma is and new patients deserve the best possible treatment right from the off.
Not only does DVRD have the potential to keep myeloma at bay for more than four years, but it means less time spent in hospital for people with myeloma and their families. We can’t emphasise enough what this means for their quality of life."
🔗Read more about DVRD here: https://brnw.ch/21x3aEv
